Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT00772486Phase 1Completed

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

Role: lead

NCT00850057Phase 1Completed

Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Role: collaborator

NCT02719015Phase 1Withdrawn

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Role: collaborator

NCT00849524Phase 2Terminated

Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Role: collaborator

NCT00942409Phase 2Terminated

Study of Repeat Intranodal Injections of Ad-ISF35

Role: collaborator

NCT00783588Phase 1Completed

A Phase I Extension Trial of Repeated Infusions of ISF35

Role: lead

NCT00779883Phase 1Completed

A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

Role: lead

All 7 trials loaded